Corbus Pharmaceuticals intends to restructure the company’s workforce and reallocate capital toward specific clinical and preclinical programs.

Final data from Gilead Sciences Inc.’s antiviral drug remdesivir showed the treatment cut Covid-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said.

Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Massachusetts-based Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis (CF).

Amgen presented five-year Phase II data in episodic migraines at the Migraine Trust Virtual Symposium showing that the anti-CGRP medication Aimovig helped patients achieve sustained reductions in monthly migraine days.

Ironwood Pharmaceuticals initiated an internal organizational restructuring that includes cutting up to 100 full-time employees from payroll following a review of unblinded data from the company’s Phase III trials for IW-3718-302, which show that the drug failed to reduce the severity of heartburn in patients with refractory gastroesophageal reflux disease (GERD).

Fujifilm Holdings Corp. said a late-stage study of Avigan showed the antiviral drug reduced recovery times for Covid-19 patients with non-severe symptoms, boosting expectations for regulatory approval in Japan.

Vaccinex announced topline data from the early manifest treatment arm of the company’s Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease (HD).

AstraZeneca released new results from the company’s ADAURA Phase III trial showing that Tagrisso (osimertinib) demonstrated clinically meaningful improvement in central nervous system disease-free survival in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC), after complete tumor resection.

Roche company Genentech presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Numerous companies presented clinical trial data and updates at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.